Jul 7, 2026 04:30PM
Jul 7, 2026 04:30PM
Jun 24, 2026 04:05PM
Jun 24, 2026 04:05PM
Jun 4, 2026 08:00AM
May 15, 2026 06:00AM
Apr 15, 2026 06:06AM ARS Pharmaceuticals gets Health Canada approval for neffy nasal spray
Apr 15, 2026 06:05AM
Mar 27, 2026 09:49AM
Mar 27, 2026 08:00AM
Mar 27, 2026 08:00AM
Mar 9, 2026 06:00AM
Mar 2, 2026 06:37AM
Feb 10, 2026 08:00AM ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific
Feb 2, 2026 08:00AM
Feb 2, 2026 08:00AM
Jan 21, 2026 08:00AM
Dec 29, 2025 08:00AM
Dec 29, 2025 08:00AM
Nov 10, 2025 06:00AM
Nov 4, 2025 08:00AM ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
Nov 3, 2025 02:23PM
Nov 3, 2025 02:23PM
Nov 3, 2025 07:45AM
Nov 3, 2025 07:45AM
Oct 8, 2025 08:00AM
Oct 8, 2025 08:00AM
Sep 29, 2025 04:06PM ARS Pharmaceuticals secures $250 million loan facility for neffy expansion
Sep 29, 2025 04:05PM
Sep 19, 2025 08:01AM
Sep 19, 2025 08:00AM
Sep 8, 2025 08:00AM
Aug 13, 2025 07:00AM
Jul 18, 2025 09:26AM
Jul 18, 2025 09:25AM EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
May 14, 2025 07:00AM
May 7, 2025 08:00AM
May 7, 2025 08:00AM
May 2, 2025 08:00AM
Mar 20, 2025 07:00AM
Mar 5, 2025 04:11PM
Mar 5, 2025 04:10PM ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
Mar 5, 2025 04:10PM
Feb 20, 2025 07:02PM
Feb 18, 2025 08:00AM
Jan 21, 2025 08:00AM
Jan 13, 2025 08:00AM
Jan 6, 2025 08:10AM
Jan 6, 2025 08:00AM ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Dec 19, 2024 05:25PM

325,726 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All